Wild-type hras suppresses the earliest stages of tumorigenesis in a genetically engineered mouse model of pancreatic cancer

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Weyandt, Jamie D ^a   Lampson, Benjamin L ^a,b   Tang, Sherry ^a   Mastrodomenico, Matthew ^a   Cardona, Diana M ^a   Counter, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; RAS PROTEIN; HRAS PROTEIN, HUMAN; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; GENETIC ENGINEERING; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE H RAS; PANCREAS ADENOCARCINOMA; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; CELL PROLIFERATION; GENETICS; HUMAN; METABOLISM; MUTATION; PANCREATIC NEOPLASMS; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84948650504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140253     Document Type: Article

References (36)

1. Surveillance, Epidemiology, and End Results [SEER] Program. National Cancer Institute, 2013. Available: www.seercancer.gov.
2. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801-1806. doi: 10.1126/science.1164368 PMID: 18772397
3. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11: 761-774. doi: 10.1038/nrc3106 PMID: 21993244
4. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014; 111: 817-822. doi: 10.1038/bjc.2014.215 PMID: 24755884
5. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003; 4: 437-450. PMID: 14706336
6. Huang DC, Marshall CJ, Hancock JF. Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. Mol Cell Biol. 1993; 13: 2420-2431. PMID: 8455619
7. Hamilton M, Wolfman A. Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo. Oncogene. 1998; 16: 1417-1428. PMID: 9525741
8. Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008; 452: 646-649. doi: 10.1038/nature06778 PMID: 18344980
9. Jeng HH, Taylor LJ, Bar-Sagi D. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat Comun. 2012; 3: 1168.
10. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2013; 3: 112-123. doi: 10.1158/2159-8290.CD-12-0231 PMID: 23103856
11. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010; 10: 51-517. doi: 10.1038/nrc2772 PMID: 20029423
12. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogeneinduced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007; 9: 493-505. PMID: 17450133
13. Balmain A, Brown K, Bremner R. The interplay between ras oncogenes and tumor suppressor genes in experimental carcinogenesis. Immunology Ser. 1990; 51: 75-788.
14. Hegi ME, Devereux TR, Dietrich WF, Cochran CJ, Lander ES, Foley JF, et al. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res. 1994; 54: 6257-6264. PMID: 7954475
15. Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 2001; 29: 25-33. PMID: 11528387
16. Li J, Zhang Z, Dai Z, Plass C, Morrison C, Wang Y, et al. LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene. 2003; 22: 1243-1246. PMID: 12606951
17. To MD, Rosario RD, Westcott PM, Banta KL, Balmain A. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene. 2013; 32: 4028-4033. doi: 10.1038/onc.2012. 404 PMID: 22945650
18. Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J, et al. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res. 2002; 62: 4514-4518. PMID: 12154063
19. Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, et al. Wild-type Hand N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell. 2014; 25: 243-256. doi: 10.1016/j.ccr.2014.01.005 PMID: 24525237
20. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated β-galactosidase [SA-βgal] activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 2009; 4: 1798-1806. doi: 10.1038/nprot.2009.191 PMID: 20010931
21. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene. 1997; 14: 623-625. PMID: 9053862
22. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, Yienger K, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001; 21: 1444-1452. PMID: 11238881
23. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011; 378: 607-620. doi: 10.1016/S0140-6736(10)62307-0 PMID: 21620466
24. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7: 469-483. PMID: 15894267
25. Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, et al. Targeting eNOS in pancreatic cancer. Cancer Res. 2012; 72: 4472-4482. doi: 10.1158/0008-5472.CAN-12-0057 PMID: 22738914
26. Mazur PK, Gruner BM, Nakhai H, Sipos B, Zimber-Strobl U, Strobl LJ, et al. Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras[G12D]-induced skin carcinogenesis in vivo. PLoS One. 2010; 5: e13578. doi: 10.1371/journal.pone.0013578 PMID: 21042537
27. Gades NM, Ohash A, Mills LD, Rowley MA, Predmore KS, Marler RJ, et al. Spontaneous vulvar papillomas in a colony of mice used for pancreatic cancer research. Comp Med. 2008; 58: 271-275. PMID: 18589869
28. Shi G, DiRenzo D, Qu C, Barney D, Miley D, Konieczny SF. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene. 2013; 32: 1950-1958. doi: 10. 1038/onc.2012.210 PMID: 22665051
29. Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res. 2010; 70: 7114-7124. doi: 10.1158/ 0008-5472.CAN-10-1649 PMID: 20807812
30. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA. 2010; 107: 246-251. doi: 10.1073/pnas.0908428107 PMID: 20018721
31. Reichert M, Rustgi AK. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest. 2011; 121: 4572-4578. doi: 10.1172/JCI57131 PMID: 22133881
32. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88: 593-602. PMID: 9054499
33. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology: Senescence in premalignant tumours. Nature. 2005; 436: 642. PMID: 16079833
34. Henis YI, Hancock JF, Prior IA. Ras acylation, compartmentalization, and signaling nanoclusters (Review). Mol Membr Biol. 2009; 26: 80-92. doi: 10.1080/09687680802649582 PMID: 19115142
35. Singh A, Sowjanya AP, Ramakrishna G. The wild type Ras road ahead. FASEB J. 2005; 19: 161-169. PMID: 15677339
36. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 2013; 3: 993-1001. doi: 10.1158/2159-8290.CD-13-0096 PMID: 23733505